Which has higher earnings & valuation, AAPG or CGON?

CG Oncology has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 18.99 -$177.71M N/A N/A CG Oncology $4.04M 1,558.78 -$160.99M -$2.33 N/A

Is AAPG or CGON more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A CG Oncology N/A -23.33% -22.24%

Does the media prefer AAPG or CGON?

In the previous week, CG Oncology had 6 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 9 mentions for CG Oncology and 3 mentions for Ascentage Pharma Group International. CG Oncology's average media sentiment score of 0.96 beat Ascentage Pharma Group International's score of 0.34 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, AAPG or XENE?

Ascentage Pharma Group International has higher revenue and earnings than Xenon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 18.99 -$177.71M N/A N/A Xenon Pharmaceuticals $7.50M 825.05 -$345.91M -$4.70 N/A

Is AAPG or XENE more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Xenon Pharmaceuticals N/A -49.23% -46.42%

Which has stronger earnings and valuation, AAPG or LGND?

Ligand Pharmaceuticals has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 18.99 -$177.71M N/A N/A Ligand Pharmaceuticals $268.09M 22.48 $124.45M $7.37 40.81

Which has better earnings and valuation, AAPG or DNTH?

Dianthus Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 18.99 -$177.71M N/A N/A Dianthus Therapeutics $2.04M 2,972.41 -$162.34M -$4.13 N/A

Which has preferable earnings & valuation, AAPG or ORKA?

Oruka Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 18.99 -$177.71M N/A N/A Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A

Is AAPG or ORKA more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Oruka Therapeutics N/A -26.16% -25.00%

Ascentage Pharma Group International (AAPG) Competitors

$16.69 -0.12 (-0.71%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$16.66 -0.04 (-0.21%)

As of 08/4/2026 07:34 PM Eastern

Compare

AAPG vs. CGON, XENE, LGND, DNTH, and ORKA

Should you buy Ascentage Pharma Group International stock or one of its competitors? MarketBeat compares Ascentage Pharma Group International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascentage Pharma Group International include CG Oncology (CGON), Xenon Pharmaceuticals (XENE), Ligand Pharmaceuticals (LGND), Dianthus Therapeutics (DNTH), and Oruka Therapeutics (ORKA). These companies are all part of the "biotechnology" industry.

How does Ascentage Pharma Group International compare to CG Oncology?

Ascentage Pharma Group International (NASDAQ:AAPG) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Ascentage Pharma Group International's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, CG Oncology had 6 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 9 mentions for CG Oncology and 3 mentions for Ascentage Pharma Group International. CG Oncology's average media sentiment score of 0.96 beat Ascentage Pharma Group International's score of 0.34 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International presently has a consensus price target of $46.43, suggesting a potential upside of 178.18%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 14.46%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ascentage Pharma Group International is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CG Oncology has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	18.99	-$177.71M	N/A	N/A
CG Oncology	$4.04M	1,558.78	-$160.99M	-$2.33	N/A

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Summary

CG Oncology beats Ascentage Pharma Group International on 8 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Xenon Pharmaceuticals?

Ascentage Pharma Group International (NASDAQ:AAPG) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Ascentage Pharma Group International's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 14 mentions for Xenon Pharmaceuticals and 3 mentions for Ascentage Pharma Group International. Xenon Pharmaceuticals' average media sentiment score of 1.30 beat Ascentage Pharma Group International's score of 0.34 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ascentage Pharma Group International has higher revenue and earnings than Xenon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	18.99	-$177.71M	N/A	N/A
Xenon Pharmaceuticals	$7.50M	825.05	-$345.91M	-$4.70	N/A

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 178.18%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 20.61%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities analysts clearly believe Ascentage Pharma Group International is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Ligand Pharmaceuticals?

Ascentage Pharma Group International (NASDAQ:AAPG) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascentage Pharma Group International has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

In the previous week, Ligand Pharmaceuticals had 11 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 14 mentions for Ligand Pharmaceuticals and 3 mentions for Ascentage Pharma Group International. Ligand Pharmaceuticals' average media sentiment score of 1.08 beat Ascentage Pharma Group International's score of 0.34 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to Ascentage Pharma Group International's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Ligand Pharmaceuticals has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	18.99	-$177.71M	N/A	N/A
Ligand Pharmaceuticals	$268.09M	22.48	$124.45M	$7.37	40.81

Ascentage Pharma Group International currently has a consensus price target of $46.43, suggesting a potential upside of 178.18%. Ligand Pharmaceuticals has a consensus price target of $326.00, suggesting a potential upside of 8.38%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascentage Pharma Group International is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Ligand Pharmaceuticals beats Ascentage Pharma Group International on 11 of the 15 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Dianthus Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 178.18%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 6.22%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascentage Pharma Group International is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Dianthus Therapeutics had 10 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 13 mentions for Dianthus Therapeutics and 3 mentions for Ascentage Pharma Group International. Dianthus Therapeutics' average media sentiment score of 0.52 beat Ascentage Pharma Group International's score of 0.34 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ascentage Pharma Group International has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Ascentage Pharma Group International's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Dianthus Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	18.99	-$177.71M	N/A	N/A
Dianthus Therapeutics	$2.04M	2,972.41	-$162.34M	-$4.13	N/A

Ascentage Pharma Group International has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Summary

Dianthus Therapeutics beats Ascentage Pharma Group International on 8 of the 15 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Oruka Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Ascentage Pharma Group International's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Oruka Therapeutics	N/A	-26.16%	-25.00%

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ascentage Pharma Group International has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 178.18%. Oruka Therapeutics has a consensus target price of $134.30, indicating a potential upside of 36.86%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascentage Pharma Group International is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	18.99	-$177.71M	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

In the previous week, Oruka Therapeutics had 6 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 9 mentions for Oruka Therapeutics and 3 mentions for Ascentage Pharma Group International. Oruka Therapeutics' average media sentiment score of 0.84 beat Ascentage Pharma Group International's score of 0.34 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascentage Pharma Group International beats Oruka Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AAPG vs. The Competition

Export

Metric	Ascentage Pharma Group International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.57B	$3.52B	$6.83B	$12.76B
Dividend Yield	N/A	3.77%	2.59%	10.01%
P/E Ratio	N/A	7.32	279.15	25.53
Price / Sales	18.99	1,269.95	592.00	94.29
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	8.18	17.07	12.95	6.11
Net Income	-$177.71M	-$12.52M	$3.48B	$347.58M
7 Day Performance	-8.85%	3.66%	3.40%	4.91%
1 Month Performance	-9.78%	-5.36%	-2.79%	-2.06%
1 Year Performance	-60.26%	49.41%	73.07%	21.03%

Ascentage Pharma Group International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AAPG Ascentage Pharma Group International	4.0939 of 5 stars	$16.69 -0.7%	$46.43 +178.2%	-55.6%	$1.57B	$82.10M	N/A	600
CGON CG Oncology	2.8579 of 5 stars	$71.17 -2.5%	$81.73 +14.8%	+173.7%	$6.28B	$5.07M	N/A	61	Positive News Upcoming Earnings Options Volume
XENE Xenon Pharmaceuticals	2.9921 of 5 stars	$63.10 -1.7%	$77.20 +22.4%	+93.0%	$6.10B	$7.50M	N/A	210	Positive News Upcoming Earnings
LGND Ligand Pharmaceuticals	4.3753 of 5 stars	$292.15 -1.4%	$319.00 +9.2%	+122.2%	$5.86B	$268.09M	39.70	80	Positive News Upcoming Earnings Analyst Forecast Insider Trade Gap Up
DNTH Dianthus Therapeutics	1.6457 of 5 stars	$106.95 -5.1%	$117.82 +10.2%	+415.9%	$5.85B	$1.34M	N/A	80	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. CGON, XENE, LGND, DNTH, and ORKA

How does Ascentage Pharma Group International compare to CG Oncology?

Summary

How does Ascentage Pharma Group International compare to Xenon Pharmaceuticals?

Summary

How does Ascentage Pharma Group International compare to Ligand Pharmaceuticals?

Summary

How does Ascentage Pharma Group International compare to Dianthus Therapeutics?

Summary

How does Ascentage Pharma Group International compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. CGON, XENE, LGND, DNTH, and ORKA

How does Ascentage Pharma Group International compare to CG Oncology?

Is AAPG or CGON more profitable?

Does the media prefer AAPG or CGON?

Do analysts rate AAPG or CGON?

Which has higher earnings & valuation, AAPG or CGON?

Do institutionals and insiders have more ownership in AAPG or CGON?

Which has more volatility & risk, AAPG or CGON?

Summary

How does Ascentage Pharma Group International compare to Xenon Pharmaceuticals?

Is AAPG or XENE more profitable?

Does the media favor AAPG or XENE?

Which has more risk and volatility, AAPG or XENE?

Do institutionals and insiders believe in AAPG or XENE?

Which has higher valuation and earnings, AAPG or XENE?

Do analysts prefer AAPG or XENE?

Summary

How does Ascentage Pharma Group International compare to Ligand Pharmaceuticals?

Do institutionals and insiders hold more shares of AAPG or LGND?

Which has more volatility and risk, AAPG or LGND?

Does the media favor AAPG or LGND?

Is AAPG or LGND more profitable?

Which has stronger earnings and valuation, AAPG or LGND?

Do analysts recommend AAPG or LGND?

Summary

How does Ascentage Pharma Group International compare to Dianthus Therapeutics?

Do analysts prefer AAPG or DNTH?

Does the media prefer AAPG or DNTH?

Do institutionals and insiders believe in AAPG or DNTH?

Is AAPG or DNTH more profitable?

Which has better earnings and valuation, AAPG or DNTH?

Which has more volatility and risk, AAPG or DNTH?

Summary

How does Ascentage Pharma Group International compare to Oruka Therapeutics?

Is AAPG or ORKA more profitable?

Do institutionals and insiders have more ownership in AAPG or ORKA?

Which has more risk and volatility, AAPG or ORKA?

Do analysts rate AAPG or ORKA?

Which has preferable earnings & valuation, AAPG or ORKA?

Does the media prefer AAPG or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools